- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences | 289 | GlobeNewswire (Europe) | OKYO demonstrates continued commitment to optometry and ophthalmology
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| Di | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.09. | OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 | 331 | GlobeNewswire (Europe) | Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09,... ► Artikel lesen | |
| 08.09. | OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference | 374 | GlobeNewswire (Europe) | LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 08.09. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.07. | OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer | 275 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 | 366 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 27.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Director | 345 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.07. | OKYO Pharma CEO purchases 15,000 shares at $1.54 each | 2 | Investing.com | ||
| 23.07. | OKYO Pharma Announces Purchase of Shares by Chief Executive Officer | 330 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 329 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma executive purchases 3,500 shares at $1.40 each | 2 | Investing.com | ||
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | 333 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 22.07. | OKYO Pharma Announces Purchase of Shares by Chief Medical Officer | 327 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference | 401 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 21.07. | OKYO Pharma chairman increases stake with share purchase | 2 | Seeking Alpha | ||
| 21.07. | OKYO Pharma Announces Purchase of Shares by Chairman | 387 | GlobeNewswire (Europe) | LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 20.07. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.07. | OKYO Pharma files annual report, raises $25M for phase 3 trial | 2 | Investing.com |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,537 | -0,04 % | PAUKENSCHLAG: Steht die Valneva-Aktie vor einer Kursexplosion? - Handeln Sie vor Montag! | ||
| PALATIN TECHNOLOGIES | 9,330 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,902 | -0,99 % | H.C. Wainwright raises Ocugen stock price target on Bahamas approval | ||
| VIVORYON THERAPEUTICS | 1,095 | -0,90 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,520 | -0,13 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| IDEXX LABORATORIES | 462,00 | +0,30 % | IDEXX Laboratories, Inc.: IDEXX erweitert den Fecal Dx Antigentest um den Nachweis von Taeniid-Bandwürmern | Das erweiterte Testmenü erkennt nun mehr Darmparasiten bei Routineuntersuchungen
IDEXX Laboratories, Inc. (NASDAQ: IDXX), global führend bei Innovationen im Bereich der Tiergesundheit, gab heute... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,200 | -2,31 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,500 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,200 | 0,00 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| VERASTEM | 6,924 | +1,17 % | Verastem presents new data on ovarian cancer drug combination | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,626 | +0,15 % | IP Group sells down stake in Oxford Nanopore | ||
| VOYAGER THERAPEUTICS | 2,230 | +3,05 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,240 | -1,32 % | Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? | ||
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.09.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 08.09.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.09.2026.ISIN NameIT0004053440... ► Artikel lesen | |
| PALISADE BIO | 1,450 | +0,69 % | Palisade Bio, Inc.: Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-1,36 %) liegt der Kurs bei 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.